ACT-128800 in Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

September 30, 2009

Conditions
Plaque Psoriasis
Interventions
DRUG

ACT-128800

ACT-128800 administered orally once daily

DRUG

Placebo

Matching placebo capsules administered orally once daily

Trial Locations (14)

1085

Semmelweis Universtity Dept. dermato-venerology and skin oncology, Budapest

1090

University Klinik of Vienna, Vienna

4012

UNIVERSITY OF DEBRECEN Department of dermatology, Debrecen

6202

CHU de Nice-Hôpital de l'Archet 2 / Service de dermatologie, Nice

6720

University of Szeged Department of dermatology and allergology, Szeged

8036

Landeskrankenhaus - Universitätsklilnikum Graz, Allgemeine Dermatologie, Graz

8200

Veszprem County Csolnoky Ferenc Hospital Dermatology Department, Veszprém

10117

Klinik für Dermatologie Venerologie und Allergologie, Berlin

18000

Clinical Centre of Nis Clinic of Dermato-venerology, Niš

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

31000

Dermatologie, Hôpital Purpan Universtité Paul Sabatier, Toulouse

48149

University Clinic Münster Clinic and Policlinic for skin diseases, Münster

55131

Department of Dermatology University Hospital Johannes Gutenberg-University Mainz, Mainz

69000

Departement de Pneumologie/ Unité Immunologie Clinique Allergie- Centre Hospitalier Lyon sud, Lyon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actelion

INDUSTRY

NCT00852670 - ACT-128800 in Psoriasis | Biotech Hunter | Biotech Hunter